Federal Register / Vol. 62, No. 51 / Monday, March 17, 1997 / Notices 12657

Submission for OMB Review;

Comment Request; ‘‘Alcoholism

Prevalence and Gene/Environment

Interactions in Native American Tribes

(a 10 Tribe Study)’’ and ‘‘A Native

American Tribe With Low Alcoholism

Prevalence: Transmission Analysis,

Linkage Analysis and Gene/

Environment Interactions (a) 1 Tribe

Study)’’

SUMMARY: Under the provisions of

Section 3506(C)(2)(a) of the Paperwork

Reduction Act of 1995, the National

Institute on Alcohol Abuse and

Alcoholism (NIAAA), National

Institutes of Health (NIH) has submitted

to the Office of Management and Budget

(OMB) a request to review and approve

the information collection listed below.

This proposed information collection

was previously in the Federal Register

on July 1, 1996, and allowed 60 days for

public comment. There were no

requests for additional information

about this data collection activity, no

public comments were received. The

purpose of this notice is to allow an

additional 30 days for public comment.

The NIH may not conduct or sponsor,

and the respondent is not required to

respond to, an information collection

that has been extended, revised, or

implemented on or after June 30, 1999,

unless it displays a currently valid OMB

control number.

Proposed Collection

Title: ‘‘Alcoholism Prevalence and

Gene/Environment Interactions in

Native American Tribes (a 10 tribe

study)’’ and ‘‘A Native American Tribe

with Low Alcoholism Prevalence:

Transmission Analysis, Linkage

Analysis and Gene/Environment

Interactions (a 1 tribe study)’’. Type of

Information Collection request: NEW.

Need and Use of Information Collection:

The information proposed for collection

in both studies will be used by the

NIAAA to define the prevalence in

alcoholism and associated problems in

tribes in which the rates of alcoholism

have been reported to be widely

divergent. Additional information will

be collected on severe trauma and

stress, alcohol availability and

socioeconomic factors to identify how

these variables interact with hereditary

factors in the development of

alcoholism and related problems.

Frequency of Response: On Occasion.

Affected Public: Individuals. Type of

Respondents: Native American adults.

Estimated Number of Respondents:

1100. Estimated Number of Responses

per Respondent: 1. Average Burden

Hours per Response: 6. And Estimated

Total Annual Burden Hours Requested:

6600. There are no Capital Costs to

report. There are no Operating or

Maintenance Costs to report.

The annual burden estimates are as

follows:

Type and number of respondents

Responses

per

respondent

Total

responses Hours Total hours

Clients:

1,100 .......................................................................................................... 1 1,100 6.0 6,600

Total Number of Respondents: 3,300

(1,100 per year).

Total Number of Responses: 3,300

(1,100 per year).

Total Hours: 19,800 (6,600 per year).

Request for Comments

Comments are invited on: (a) Whether

the proposed collection is necessary,

including whether the information has

practical use; (b) ways to enhance the

clarity, quality, and use of the

information to be collected; (c) the

accuracy of the agency estimate of

burden of the proposed collection; and

(d) ways to minimize the collection

burden of the respondents. Send written

comments to Ms. Ronni Nelson,

Laboratory of Neurogenetics, Division of

Intramural Clinical and Biological

Research, NIAAA, NIH, DANAC4 (Flow

Labs), 12501 Washington Ave.,

Rockville, Maryland 20852.

Direct Comments to OMB

Written comments and/or suggestions

regarding the item(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time should be directed to the

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, DC 20503, Attention: Desk

Officer for NIH.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

the data collection plans, contact Ms.

Ronni Nelson, Laboratory of

Neurogenetics, Division of Intramural

Clinical and Biological Research

(DICBR), NIAAA, DANAC4 (Flow Labs),

12501 Washington Ave., Rockville,

Maryland 20852, or call non-toll-free

number (301) 443–5781.

COMMENTS DUE DATE: Comments

regarding this information collection are

best assured of having their full effect if

received on or before April 16, 1997.

Dated: March 10, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97–6637 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute

SUMMARY: The National Institutes of

Health is seeking Cooperative Research

and Development Agreement (CRADA)

partners for the future development and

commercialization of Active

Transglutaminase I.

To speed the research and

development of this compound, the

National Institutes of Health is seeking

a CRADA partner, in accordance with

the Federal Technology Transfer Act of

1986, 15 U.S.C. 3710(a)(b), with

capabilities to produce high grade

quantities of the enzyme for further

characterization and research in

accordance with the regulations

governing the transfer of Governmentdeveloped agents. Any proposals to

produce and develop active

Transglutaminase I will be considered.

ADDRESSES: CRADA proposals and

questions about this opportunity should

be addressed to: Ms. Sue Patow,

Technology Transfer, NHLBI, Building

31, Room 1B30, Bethesda, MD 20892

(301–402–5579) or E-mail proposals and

questions to: <PatowS@nih. gov>.

SUPPLEMENTARY INFORMATION: A supply

of active human transflutaminase I

enzyme (TG1) for therapeutic research is

required. For this purpose a suitable

protein expression system should be

available (mammalian, insect or

microorganism) which will utilize DNA

we provide that codes for TG1.

production of 5 mg or more TG1 protein

may be required for sufficient enzyme

activity, but the exact quantity and

frequency of supply will depend on the

stability and activity of the product.

Minimally purified TG1 enzyme will be

accepted for initial tests, but more

purified enzyme may subsequently be

required. The exact form of the TG1

enzyme to be supplied will depend on